<DOC>
	<DOCNO>NCT00061880</DOCNO>
	<brief_summary>RATIONALE : BCX-1777 may stop growth cancer cell block enzymes necessary cancer cell growth . PURPOSE : Phase I/II trial study effectiveness BCX-1777 treating patient refractory cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>BCX-1777 Treating Patients With Refractory Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose BCX-1777 patient refractory cutaneous T-cell lymphoma . - Determine efficacy drug patient . - Determine toxicity profile drug patient . - Correlate plasma concentration deoxyguanosine clinical response toxicity patient treated drug . - Determine provisional optimal biological dose drug patient . OUTLINE : This open-label , nonrandomized , dose-escalation , multicenter study . - Phase I : Patients receive BCX-1777 IV 30 minute every 12 hour day 1-5 ( total 9 dos ) . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BCX-1777 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive treatment phase I MTD BCX-1777 . Patients ( include respond treatment ) follow 14 30 day , monthly 6 month , every 2 month 6 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 3-64 patient ( 3-24 phase I 40 phase II ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous Tcell lymphoma ( CTCL ) Any stage except IA patch Previously treat accord 1 following : Stage IA plaque , IB , IIA : At least 4 prior conventional and/or experimental regimen ( topical systemic , include psoralenultraviolet light [ PUVA ] systemic corticosteroid ) Stage IIB , III , IV : At least 1 prior systemic regimen ( systemic corticosteroid PUVA count systemic regimen purpose ) NOTE : Repeated use regimen consider one regimen Measurable disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03 Life expectancy At least 3 month Hematopoietic Granulocyte count least 2,000/mm^3 Platelet count least 75,000/mm^3 Hemoglobin least 10.0 g/dL Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) ( unless due Gilbert 's syndrome ) ALT great 2 time ULN Alkaline phosphatase great 2 time ULN No hepatitis B C Renal Creatinine clearance least 45 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative Human Tcell leukemia virus type 1 ( HTLV1 ) negative No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No illness would limit study participation No active serious infection control antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent anticancer antibody therapy No concurrent anticancer immunotherapy No concurrent anticancer gene therapy No concurrent anticancer vaccine therapy No concurrent anticancer angiogenesis inhibitors No concurrent sargramostim ( GMCSF ) No concurrent filgrastim ( GCSF ) course 1 therapy Chemotherapy More 21 day since prior chemotherapy unless fully recover No concurrent anticancer chemotherapy Endocrine therapy See Disease Characteristics More 2 week since prior topical corticosteroid No concurrent anticancer hormonal therapy Radiotherapy More 2 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other More 2 week since prior antineoplastic therapy More 21 day since prior investigational agent unless fully recover No concurrent citrateblood product within 30 minute study treatment No concurrent anticancer matrix metalloprotease inhibitors No concurrent antiCTCL therapy No concurrent use tan bed No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
</DOC>